Academic Journal
أعرض في EDS

Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer

التفاصيل البيبلوغرافية
العنوان: Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
المؤلفون: Chaohui Lisa Zhao, Kamaljeet Singh, Alexander S. Brodsky, Shaolei Lu, Theresa A. Graves, Mary Anne Fenton, Dongfang Yang, Ashlee Sturtevant, Murray B. Resnick, Yihong Wang
المصدر: BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
بيانات النشر: BMC, 2019.
سنة النشر: 2019
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Collagen, Tumor infiltrating lymphocytes, Tumor microenvironment, Breast cancer, Adjuvant chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen α1 (ColXα1) and low TILs correlated with poor pathologic response to neoadjuvant therapy in estrogen receptor and HER2-positive (ER+/HER2+) breast cancer. Here, we investigate the relationship of ColXα1 and long-term outcome of ER+/HER2+ breast cancer patients in an adjuvant setting. Methods A total of 164 cases with at least 5-year follow-up were included. Immunohistochemistry for ColXα1 was performed on whole tumor sections. Associations between ColXα1expression, clinical pathological features, and outcomes were analyzed. Results ColXα1 expression was directly proportional to the amount of tumor associated stroma (p = 0.024) and inversely proportional to TILs. Increased ColXα1 was significantly associated with shorter disease free survival and overall survival by univariate analysis. In multivariate analysis, OS was lower in ColXα1 expressing (HR = 2.1; 95% CI = 1.2–3.9) tumors of older patients (> = 58 years) (HR = 5.3; 95% CI = 1.7–17) with higher stage (HR = 2.6; 95% CI = 1.3–5.2). Similarly, DFS was lower in ColXα1 expressing (HR = 1.8; 95% CI = 1.6–5.7) tumors of older patients (HR = 3.2; 95% CI = 1.3–7.8) with higher stage (HR = 2.7; 95% CI = 1.6–5.7) and low TILs. In low PR+ tumors, higher ColXα1 expression was associated with poorer prognosis. Conclusion ColXα1 expression is associated with poor disease free survival and overall survival in ER+/HER2+ breast cancer. This study provides further support for the prognostic utility of ColXα1 as a breast cancer associated stromal factor that predicts response to chemotherapy.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1471-2407
Relation: http://link.springer.com/article/10.1186/s12885-019-6134-y; https://doaj.org/toc/1471-2407
DOI: 10.1186/s12885-019-6134-y
URL الوصول: https://doaj.org/article/f91ad71a403846a2922564339a7eac6e
رقم الانضمام: edsdoj.f91ad71a403846a2922564339a7eac6e
قاعدة البيانات: Directory of Open Access Journals
ResultId 1
Header edsdoj
Directory of Open Access Journals
edsdoj.f91ad71a403846a2922564339a7eac6e
929
3
Academic Journal
academicJournal
928.820922851563
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.f91ad71a403846a2922564339a7eac6e&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doaj.org/article/f91ad71a403846a2922564339a7eac6e [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=14712407&ISBN=&volume=19&issue=1&date=20191101&spage=1&pages=1-8&title=BMC Cancer&atitle=Stromal%20ColX%CE%B11%20expression%20correlates%20with%20tumor-infiltrating%20lymphocytes%20and%20predicts%20adjuvant%20therapy%20outcome%20in%20ER-positive%2FHER2-positive%20breast%20cancer&id=DOI:10.1186/s12885-019-6134-y [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Chaohui+Lisa+Zhao%22">Chaohui Lisa Zhao</searchLink><br /><searchLink fieldCode="AR" term="%22Kamaljeet+Singh%22">Kamaljeet Singh</searchLink><br /><searchLink fieldCode="AR" term="%22Alexander+S%2E+Brodsky%22">Alexander S. Brodsky</searchLink><br /><searchLink fieldCode="AR" term="%22Shaolei+Lu%22">Shaolei Lu</searchLink><br /><searchLink fieldCode="AR" term="%22Theresa+A%2E+Graves%22">Theresa A. Graves</searchLink><br /><searchLink fieldCode="AR" term="%22Mary+Anne+Fenton%22">Mary Anne Fenton</searchLink><br /><searchLink fieldCode="AR" term="%22Dongfang+Yang%22">Dongfang Yang</searchLink><br /><searchLink fieldCode="AR" term="%22Ashlee+Sturtevant%22">Ashlee Sturtevant</searchLink><br /><searchLink fieldCode="AR" term="%22Murray+B%2E+Resnick%22">Murray B. Resnick</searchLink><br /><searchLink fieldCode="AR" term="%22Yihong+Wang%22">Yihong Wang</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019) )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => BMC, 2019. )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Collagen%22">Collagen</searchLink><br /><searchLink fieldCode="DE" term="%22Tumor+infiltrating+lymphocytes%22">Tumor infiltrating lymphocytes</searchLink><br /><searchLink fieldCode="DE" term="%22Tumor+microenvironment%22">Tumor microenvironment</searchLink><br /><searchLink fieldCode="DE" term="%22Breast+cancer%22">Breast cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Adjuvant+chemotherapy%22">Adjuvant chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Abstract Background The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen α1 (ColXα1) and low TILs correlated with poor pathologic response to neoadjuvant therapy in estrogen receptor and HER2-positive (ER+/HER2+) breast cancer. Here, we investigate the relationship of ColXα1 and long-term outcome of ER+/HER2+ breast cancer patients in an adjuvant setting. Methods A total of 164 cases with at least 5-year follow-up were included. Immunohistochemistry for ColXα1 was performed on whole tumor sections. Associations between ColXα1expression, clinical pathological features, and outcomes were analyzed. Results ColXα1 expression was directly proportional to the amount of tumor associated stroma (p = 0.024) and inversely proportional to TILs. Increased ColXα1 was significantly associated with shorter disease free survival and overall survival by univariate analysis. In multivariate analysis, OS was lower in ColXα1 expressing (HR = 2.1; 95% CI = 1.2–3.9) tumors of older patients (> = 58 years) (HR = 5.3; 95% CI = 1.7–17) with higher stage (HR = 2.6; 95% CI = 1.3–5.2). Similarly, DFS was lower in ColXα1 expressing (HR = 1.8; 95% CI = 1.6–5.7) tumors of older patients (HR = 3.2; 95% CI = 1.3–7.8) with higher stage (HR = 2.7; 95% CI = 1.6–5.7) and low TILs. In low PR+ tumors, higher ColXα1 expression was associated with poorer prognosis. Conclusion ColXα1 expression is associated with poor disease free survival and overall survival in ER+/HER2+ breast cancer. This study provides further support for the prognostic utility of ColXα1 as a breast cancer associated stromal factor that predicts response to chemotherapy. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article )
Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1471-2407 )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://link.springer.com/article/10.1186/s12885-019-6134-y; https://doaj.org/toc/1471-2407 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1186/s12885-019-6134-y )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/f91ad71a403846a2922564339a7eac6e" linkWindow="_blank">https://doaj.org/article/f91ad71a403846a2922564339a7eac6e</link> )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.f91ad71a403846a2922564339a7eac6e )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1186/s12885-019-6134-y ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 8 [StartPage] => 1 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Collagen [Type] => general ) [1] => Array ( [SubjectFull] => Tumor infiltrating lymphocytes [Type] => general ) [2] => Array ( [SubjectFull] => Tumor microenvironment [Type] => general ) [3] => Array ( [SubjectFull] => Breast cancer [Type] => general ) [4] => Array ( [SubjectFull] => Adjuvant chemotherapy [Type] => general ) [5] => Array ( [SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens [Type] => general ) [6] => Array ( [SubjectFull] => RC254-282 [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chaohui Lisa Zhao ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kamaljeet Singh ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Alexander S. Brodsky ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shaolei Lu ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Theresa A. Graves ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Mary Anne Fenton ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dongfang Yang ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ashlee Sturtevant ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Murray B. Resnick ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yihong Wang ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 11 [Type] => published [Y] => 2019 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 14712407 ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 19 ) [1] => Array ( [Type] => issue [Value] => 1 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => BMC Cancer [Type] => main ) ) ) ) ) ) )
IllustrationInfo